LC-MS/MS METHOD FOR SIMULTANEOUS QUANTIFICATION OF SERIES OF AMINOPROPAN-2-OL DERIVATIVES-APPLICATION TO IN VIVO PHARMACOKINETIC STUDY

REFERENCES

• Stoschitzky , K. ; Koshucharova , G. ; Zweiker , R. ; Maier , R. ; Watzinger , N. ; Fruhwald , F. M. ; Klein , W. Differing Beta-Blocking Effects of Carvedilol and Metoprolol . Eur. J. Heart Fail. 2001 , 3 , 343 – 349 .
   PubMed Web of Science ®Google Scholar
• Panjrath , G. S. ; Messerli , F. H. Beta-Blockers for Primary Prevention in Hypertension: Era Bygone? Cardiovasc. Dis. 2006 , 49 ( 2 ), 76 – 87 .
   Google Scholar
• Poole-Wilson , P. ; Swedberg , K. ; Cleland , J. ; Di Lenarda , A. ; Hanrath , P. ; Komajda , M. ; Lubsen , J. ; Lutiger , B. ; Metra , M. ; Remme , W. ; Torp-Pedersen , C. ; Scherhag , A. ; Skene , A. Comparison of Carvedilol and Metoprolol on Clinical Outcomes in Patients with Chronic Heart Failure in the Carvedilol or Metoprolol European Trial (COMET): Randomized Controlled trial . Lancet 2003 , 362 ( 9377 ), 7 – 13 .
   PubMed Web of Science ®Google Scholar
• Mehvar , R. ; Brocks , D. R. Stereospecific Pharmacokinetics and Pharmacodynamics of Beta-Adrenergic Blockers in Humans . J. Pharm. Pharm. Sci. 2001 , 4 ( 2 ), 185 – 200 .
   PubMed Web of Science ®Google Scholar
• Macka , Ch. ; Elter , T. ; Bohm , M. Beta-Blocker Treatment of Chronic Heart Failure: Comparison of Carvedilol and Metoprolol . CHF 2003 , 9 ( 5 ), 241 – 250 .
   Google Scholar
• Dulin , B. ; Abraham , W. T. Pharmacology of Carvedilol . Am. J. Cardiol. 2004 , 93 ( suppl ), 3B – 6B .
   PubMed Web of Science ®Google Scholar
• Groszek , G. ; Bednarski , M. ; Dybała , M. ; Filipek , B. Synthesis and Adrenolytic Activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and Its Enantiomers. Part 1 . Eur. J. Med. Chem. 2008 , 44 ( 2 ), 809 – 817 .
   PubMed Web of Science ®Google Scholar
• Groszek , G. ; Nowak-Król , A. ; Wdowik , T. ; Świerczyński , D. ; Bednarski , M. ; Otto , M. ; Walczak , M. ; Filipek , B. Synthesis and Adrenolytic Activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol Analogs and Its Enantiomers. Part 2 . Eur. J. Med. Chem. 2009 , 44 ( 12 ), 5103 – 5111 .
   PubMed Web of Science ®Google Scholar
• Walczak , M. ; Szafarz , M. ; Szymura-Oleksiak , J. ; Groszek , G. ; Bednarski , M. ; Filipek , B. Application of Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of New Nonselective Beta-Adrenergic Blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy) ethylo]amino}propan-2-ol (2F109) in Rat Plasma . Chirality 2007 , 19 ( 7 ), 536 – 541 .
   PubMed Web of Science ®Google Scholar
• Walczak , M. ; Szymura-Oleksiak , J. ; Groszek , G. Enantioselective LC/ESI-MS/MS Analysis and Pharmacokinetic and Tissue Distribution Study of (2RS)-1-(7-Methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in Rats . Chirality 2012 , 24 ( 8 ), 591 – 599 .
   PubMed Web of Science ®Google Scholar
• Jawien , W. Variability of the Model-Independent AUC: The One Sample Per Individual Case . J. Pharmacokinet. Biopharm. 1999 , 27 ( 4 ), 437 – 464 .
   PubMedGoogle Scholar
• Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/ljlc.
   Google Scholar